Sanofi-Aventis to spend up to $1.1 billion in eyecare and cancer deals
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis is to acquire the French R&D company Fovea Pharmaceuticals for up to €370 million ($541 million) in order to expand its ophthalmology business. It has also signed a licensing deal with Merrimack Pharmaceuticals that could be worth up to $530 million to the private US company.